Dermatophytic Onychomycosis Treatment Market Business Overview 2022, and Forecast to 2030 | CAGR 7.4%

In accordance with the Dermatophytic Onychomycosis Treatment market is set to grow at a CAGR of 5.6% over a forecast period (2022-2030).

Dermatophytic Onychomycosis, also known as tinea unguium, is a fungal nail infection caused by dermatophytes. Dermatophytes are fungi that require keratin for growth. Dermatophytic Onychomycosis is the most common nail infection and it affects toenails and fingernails. Increasing prevalence of dermatophytic onychomycosis is a major factor boosting growth of the global dermatophytic onychomycosis treatment market over the forecast period. For instance, the study, 'Dermatophytosis: Prevalence of Dermatophytes and Non-Dermatophyte Fungi from Patients Attending Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia' published in the journal Dermatology Research and Practice in October 2018, demonstrated that the prevalence of dermatophytosis was 66.98% in Ethiopia.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)
https://www.contrivedatuminsights.com/request-sample/8735

The "Dermatophytic Onychomycosis Treatment Market" Report includes qualitative and quantifiable insights into the major drivers, restraints, opportunities, and challenges affecting global market growth. The examination contains complete statistical market data on the major companies, as well as revenue forecasts. The Dermatophytic Onychomycosis Treatment market study also includes information on the sales growth of many regional and country-level markets, as well as the competitive landscape and specific company analysis for the forecast period. The market report observes future growth aspects as well as the current status of market share, penetration of various types, technologies, applications, and geographies through 2030.
Dermatophytic Onychomycosis Treatment Market

Leading Players:
Bausch Health Companies, Novartis AG, Johnson and Johnson, Galderma S.A., Celtic Pharmaceuticals, Anacor Pharmaceuticals

Recent Development:
In July 2021, Almirall S.A. entered into a license and distribution agreement with Kaken Pharmaceutical. This will give it exclusive rights to develop as well as commercialize topical formulation of efinaconazole in Europe.
In November 2017, BRIEF-Kaken Pharmaceutical signed a distribution agreement exclusively for Clenafin/Jublia in Taiwan. This agreement aims to accelerate their product sales in Japan.
In September 2016, Erchonia Corp. received 510(k) approval from the U.S. FDA for its low-level Lunula Laser. It is the first low-level laser for the treatment of onychomycosis or nail fungus that received marketing clearance.

This Research Considers the following Regions on Prime focus:
North America (U.S., Canada)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
South America (Mexico, Brazil, Argentina, Columbia, Rest of South America)
Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Regional Overview:
In Europe, the demand for dermatophytic onychomycosis treatment is likely to propel owing to the increasing prevalence of onychomycosis, favoring health reimbursement, and improved distribution of OTC drugs through collaborations with retail pharmacies such as Walmart, Walgreens, and others. According to an article published in the Journal of the European Academy of Dermatology and Venereology, the prevalence of onychomycosis in Europe is 4.3%. This is anticipated to fuel the market in Europe.

Global Dermatophytic Onychomycosis Treatment Market Segmentation:
By type:
Prescribed
Over-the-Counter (OTC)

By Product Type:
Tablets
Nail Paints

By Route of Administration:
Oral
Topical

By application:
Hospitals & Clinics
Retail Pharmacies
Online Channels

Year Considered Estimating the Market Size:
Base Year of the Analysis: 2021
Historical Period: 2016-2021
Forecast Period: 2023-2029

Get Research Report within 48 Hours @
https://www.contrivedatuminsights.com/product-report/dermatophytic-onychomycosis-treatment-market-insights-2020-global-and-chinese-analysis-and-forecast-to-2027-8735/

Report Aim and Scope:
• An overview of the Dermatophytic Onychomycosis Treatment market based on geographical scope, segmentation, and financial performance of key players is presented in the report.
• The report presents the estimated Dermatophytic Onychomycosis Treatment market size by the end of the forecast period. Additionally, the historical and current market size is also examined in the report.
• Based on various indicators, the Year-on-Year Growth (%) and compound annual growth rate (CAGR) for the given forecast period are offered.
• The report presents current trends in the industry and the future scope of the market in North America, Asia Pacific, Europe, Latin America, and Europe.
• The various parameters accelerating the growth of the Dermatophytic Onychomycosis Treatment market is incorporated in the research report.
• The report analyzes the growth rate, market size, and valuation of the market during the forecast period.

Key Reasons to Purchase:
- To gain insightful analyses of the market and have a comprehensive understanding of the global market and its industrial landscape.
- To identify and analyze the profile of leading players operating in the global Dermatophytic Onychomycosis Treatment market.
- To understand the most affecting driving and restraining forces in the market and their impact on the global market.

Buy report here:
https://www.contrivedatuminsights.com/buy/8735

Contact Us:
Anna B. (Head Of sales) | Contrive Datum Insights
Contact No- IND: +91 9834816757 / CANADA: +1 2152974078
enquiry@contrivedatuminsights.com

About Us:
Contrive Datum Insights (CDI) is a global delivery partner of market intelligence and consulting services to officials in various sectors including investment, information technology, telecommunications, consumer technology, and manufacturing markets. CDI helps investment communities, business executives and IT professionals make accurate, statistically-based decisions on technology purchases and promote strong growth tactics to maintain market competitiveness. Composed of a team of more than 100 analysts and a cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and national experience.

This release was published on openPR.